EFEK TERAPI BRONKODILATOR DAN KORTIKOSTEROID TERHADAP PERUBAHAN NILAI ARUS PUNCAK EKSPIRASI (APE) PASIEN PENYAKIT PARU OBSTRUKTIF KRONIK (PPOK)
DOI:
https://doi.org/10.51771/fj.v1i2.81Keywords:
Bronchodilator, corticosteroid, peak expiratory flow, chronic obstructive pulmonary disease (COPD)Abstract
Chronic obstructive pulmonary disease (COPD) is a disorder that occurs in the respiratory tract, which is characterized by narrowing, chronic obstruction of airway flow and causing shortness of breath. Bronchodilators and corticosteroids are the first-line therapy for COPD. Appropriate and effective therapeutic management can reduce COPD morbidity and mortality. However, we still found some problems related to the effectiveness of therapy in hospitalized COPD patients. One of the important parameters that need to be monitored in COPD patients is the peak expiratory flow. The purpose of this study was to determine the effect of the use of bronchodilators and corticosteroids on the peak expiratory flow value of COPD patients. This research was conducted at Persahabatan Hospital Jakarta with a cross-sectional study design. The sample that used in this study was patient medical records for the period 2018. The inclusion criteria were patient who diagnosed with COPD, received bronchodilator and corticosteroid therapy and had complete peak expiratory flow value. The number of samples is 99 and determined through purposive sampling. The data were analyzed statistically using paired t-test. The results of this study showed that bronchodilator and corticosteroid therapy could increase the peak expiratory flow value of COPD patients by (49.85±43.61) L/minute or (46.05±51.15) %. A total of 94.95% of patients experienced an increase in peak expiratory flow values and 73.74% patients had an increase in peak expiratory flow ≥ 15%. Bronchodilator and corticosteroids had a significant effect on the peak expiratory current in COPD patients (p=0.000).
References
Global Initiative for Chronic Obstructive Lung Disease. (2021). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2021 Report (hlm. 164).
Hathasary, R. H., Wiyono, W., & Mpila, D. A. (2021). Evaluasi Penggunaan Obat pada Pasien Ppok (Penyakit Paru Obstruktif Kronis) di Instalasi Rawat Jalan RSUP Prof. Dr. R.D. Kandou Manado. PHARMACON, 10(1), 630–638. https://doi.org/10.35799/pha.10.2021.32748
Kementerian Kesehatan RI. (2011). Modul Penggunaan Obat Rasional. Jakarta: Kementerian Kesehatan RI.
Kementerian Kesehatan RI. (2013). Laporan Nasional Riskesdas 2013. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI.
Kementerian Kesehatan RI. (2015). Petunjuk Teknis Penerapan Pendekatan Praktis Kesehatan Paru di Indonesia. Jakarta: Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Kementerian Kesehatan RI.
Mirici, A., Meral, M., & Akgun, M. (2003). Comparison of the Efficacy of Nebulised Budesonide with Parenteral Corticosteroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Clinical Drug Investigation, 23(1), 55–62. https://doi.org/10.2165/00044011-200323010-00007
Perhimpunan Dokter Paru Indonesia. (2011). Penyakit Paru Obstruktif Kronik (PPOK) Edisi Buku Lengkap, Pedoman Diagnosis Dan Penatalaksanaan di Indonesia. Jakarta.
Reisner, C., Rennard, S. I., Forgaty, C., Fischer, T., St Rose, E., Fernandez, C., & Orevillo, C. (2012). Pearl Therapeutics’ Combination LAMA/LABA MDI (GFF-MDI, PT003) Provides A Significant Benefit On Home Peak Expiratory Flow Rate (PEFR) And Reduces The Need For Rescue Albuterol Use Compared To Its Components Administered Alone, Spiriva® Handihaler®, And Foradil® Aerolizer® In A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study In Patients With COPD | A101. PHARMACOLOGICAL TREATMENT OF COPD: OLD AND NEW. American Thoracic Society International Conference Meetings Abstracts. (world). https://doi.org/10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A2259
Riley, C. M., & Sciurba, F. C. (2019). Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. JAMA, 321(8), 786–797. https://doi.org/10.1001/jama.2019.0131
Saminan, S. (2016). Efek Perilaku Merokok Terhadap Saluran Pernapasan. Jurnal Kedokteran Syiah Kuala, 16(3), 191–194.
Simarmata, O. S., Lolong, D. B., Pangaribuan, L., Sulistiyowati, N., & Sulistiowati, E. (2018). Penyebab Kematian di Kabupaten Gianyar Tahun 2010-2012. Buletin Penelitian Kesehatan, 46(2), 77–86. https://doi.org/10.22435/bpk.v46i2.7
Sugiharta, S. (2016). Evaluasi Pengobatan Bronkodilator Dan Kortikosteroid Pada Pasien PPOK Di Instalasi Rawat Inap B RSUP Fatmawati Jakarta Periode Januari 2012-Juni 2013. SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL, 1(1), 76–88.
Veryanti, P. R., & Wulandari, A. (2020a). Analisis Efektivitas Biaya Penggunaan Bronkodilator dibandingkan Kombinasi Bronkodilator-Kortikosteroid pada Pasien Penyakit Paru Obstruktif Kronik (PPOK). Jurnal Farmasi Udayana, 13–18. https://doi.org/10.24843/JFU.2020.v09.i01.p02
Veryanti, P. R., & Wulandari, A. (2020b). Effectiveness of Bronchodilator and Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD). Journal of Pharmaceutical Science and Application, 2(1), 17–22. https://doi.org/10.24843/JPSA.2020.v02.i01.p03
